Sight Sciences Inc.

May 18, 2020

Sight Sciences Announces Positive Clinical Results from Randomized, Controlled Trial of TearCare for the Treatment of Dry Eye Disease

May 07, 2020

Sight Sciences Introduces the Next-Generation OMNI® Surgical System for Microinvasive Glaucoma Surgery

Mar 30, 2020

Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology

Mar 18, 2020

Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners

Mar 10, 2020

Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucoma

Dec 09, 2019

Sight Sciences Appoints Erica Rogers to its Board of Directors

Oct 22, 2019

International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI® Surgical System Predicate Device (VISCO360®)

Sep 04, 2019

Sight Sciences Raises $56M of Growth Capital to Lead the Development of the Standalone MIGS Market and Procedure-Based Dry Eye Market

Aug 07, 2019

Sight Sciences Hires Leading Industry Executives to Drive Continued Growth

Apr 30, 2019

Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System

Oct 23, 2018

Reay H. Brown, M.D., Joins Sight Sciences as Chief Medical Officer

Jan 04, 2018

Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI(TM) Surgical System

Oct 09, 2017

Sight Sciences Secures $10MM in Oversubscribed Series C Financing